Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
The K4 peptide
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "The K4 peptide" in MCE Product Catalog:
Cat. No.: HY-P5600
CAS No.: 1163064-86-5
15
15 Publications Verification
Cat. No.: HY-16993
CAS No.: 1801787-56-3
OICR-9429, a chemical probe, is high affinity WD repeat domain 5 (WDR5) inhibitor, competitively blocks WDR5 interaction with MLL protein via binding the central peptide-binding pocket of WDR5. OICR-9429 can suppress histone H3K4 trimethylation and can be used for the research of various cancers including non-MLL-rearranged leukaemia, colon, pancreatic, prostate cancer and bladder cancer (BCa) .
7
7 Cited Publications
Research Areas:
A-366, a chemical probe, is a potent, highly selective, peptide-competitive histone methyltransferase G9a inhibitor with IC50s of 3.3 and 38 nM for G9a and GLP (EHMT1), respectively. A-366 shows >1000-fold selectivity over 21 other methyltransferases. A-366 is also a potent, nanomolar inhibitor of the Spindlin1-H3K4me3-interaction (IC50=182.6 nM). A-366 displays high affinity at human histamine H3 receptor (Ki=17 nM) and shows subtype selectivity among subsets of the histaminergic and dopaminergic receptor families .
3
3 Cited Publications
Target:
Research Areas:
MS31 trihydrochloride is a potent, highly affinity and selective fragment-like methyllysine reader protein spindlin 1 (SPIN1) inhibitor. MS31 trihydrochloride potently inhibits the interactions between SPIN1 and H3K4me3 (IC50=77 nM, AlphaLISA; 243 nM, FP). MS31 trihydrochloride selectively binds Tudor domain II of SPIN1 (Kd=91 nM). MS31 trihydrochloride potently inhibits binding of trimethyllysine-containing peptides to SPIN1, and is not toxic to nontumorigenic cells .
1
1 Cited Publications
Cat. No.: HY-P2256
Target:
Research Areas:
Cat. No.: HY-403538
CAS No.: 1358901-59-3
Target:
Research Areas:
iZMYND8-34 is a ZMYND8 inhibitor with an IC50 of 0.66 μM. iZMYND8-34 inhibits the binding of H3K4me1–H3K14ac peptide to the ZMYND8 protein. iZMYND8-34 inhibits ZMYND8’s histone recognition. iZMYND8-34 blocks neuroendocrine prostate cancer development .
Cat. No.: HY-P2255
Target:
Research Areas:
Cat. No.: HY-P11456A
Cat. No.: HY-P2257
Target:
Research Areas:
Cat. No.: HY-P11456
Cat. No.: HY-125837
CAS No.: 2366264-12-0
Target:
Research Areas:
MS31 is a potent, highly affinity and selective fragment-like methyllysine reader protein spindlin 1 (SPIN1) inhibitor. MS31 potently inhibits the interactions between SPIN1 and H3K4me3 (IC50=77 nM, AlphaLISA; 243 nM, FP). MS31 selectively binds Tudor domain II of SPIN1 (Kd=91 nM). MS31 potently inhibits binding of trimethyllysine-containing peptides to SPIN1. MS31 is not toxic to nontumorigenic cells .
Cat. No.: HY-P10819
Target:
Research Areas:
Cat. No.: HY-185982
Target:
Research Areas:
Ale-a12K4 is a peptide-derived ionizable lipid originating from a12K4. Ale-a12K4 mediates the targeted delivery of mRNA to bone tissues. Ale-a12K4 can be used for the preparation of lipid nanoparticles .
Cat. No.: HY-185976
Am-KYa12K4 is a peptide-ionizable lipid (PIL) that can be incorporated into lipid nanoparticles (LNPs) to deliver mRNA to the thymus with high specificity. LNPs formulated with Am-KYa12K4 significantly enhance mRNA expression in the thymus .
Cat. No.: HY-185985
CAS No.: 3113145-60-8
Target:
Research Areas:
Am-Ka12K4 is a weakly positively charged peptide-based ionizable lipid. Am-Ka12K4 induces membrane disruption under endosomal pH conditions and possesses high lipid fusion capacity. Am-Ka12K4 forms tightly packed, stable lipid nanoparticles. Am-Ka12K4 mediates in vivo mRNA delivery, exhibits inherent liver tropism, and can be modified to adjust organ tropism, enabling selective mRNA delivery to the spleen, lung, or thymus. Am-Ka12K4 is applicable to research related to repetitive mild traumatic brain injury .
Cat. No.: HY-183602
Target:
Research Areas:
FRC-303 is a CHD1 inhibitor with a Kd of 0.14 μM and an IC50 of 0.18 μM. FRC-303 binds to the H3K4me3 binding site of CHD1 tandem chromodomain, forms aromatic cage interactions and extended ligand contacts, acts as a methyl-lysine mimic, and occupies natural peptide ligand-binding regions. FRC-303 can be used for the research of prostate cancer .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
